Last edition
News about
Boehringer Ingelheim Appoints Meenal Gauri as Managing Director for India and South Asia
Boehringer Ingelheim has named Meenal Gauri as Managing Director India, effective January 12, 2026, overseeing operations across five South Asian markets and joining the company’s India board.
Bristol Myers Squibb Reports Positive Phase II Data for Reblozyl in Alpha-Thalassemia
Bristol Myers Squibb’s Phase II trial shows Reblozyl significantly improved haemoglobin levels in non-transfusion-dependent patients and reduced transfusion burden in transfusion-dependent alpha-thalassemia, meeting all primary and key secondary endpoints.
Integris Medtech Secures SEBI Nod for INR 925 Crore IPO
Integris Medtech, the second-largest Indian-headquartered diversified medical technology platform by operating revenue in FY25, has received approval from the Securities and Exchange Board of India (SEBI) to proceed with its proposed initial public offering (IPO).
Fortress Biotech Unit Cyprium to Sell Rare Pediatric PRV for USD 205 Million
Fortress Biotech Inc and its majority-owned subsidiary Cyprium Therapeutics Inc announced that Cyprium has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of USD 205 million, subject to closing.
Angelini Pharma, Quiver Bioscience Ink USD 120 Million Pact to Develop Genetic Epilepsy Therapies
Angelini Pharma and Quiver Bioscience have signed a multi-year collaboration to develop novel therapies for genetic epilepsies, combining AI-driven discovery tools with epilepsy expertise in a deal worth up to USD 120 million.
Astellas-Vir Partnership Advances Dual-Masked T-Cell Engager for Advanced Prostate Cancer
Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to develop and commercialize VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE) targeting prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer.
Frontier Biotechnologies Inc. Signs USD 1 Billion siRNA Licensing Deal with GSK
Frontier Biotech has granted GSK exclusive global rights to two siRNA drug candidates in a deal worth up to USD 1 billion, strengthening its international expansion and immunology pipeline focus.
MHRA Approves Brensocatib as First Targeted Treatment for Non-Cystic Fibrosis Bronchiectasis in UK
UK regulator grants marketing authorisation to brensocatib (Brinsupri) for patients aged 12 and above with recurrent non-cystic fibrosis bronchiectasis flare-ups.
Lupin Secures European Commission Approval for Ranluspec, Biosimilar Ranibizumab
European Commission clears Lupin’s biosimilar ranibizumab, Ranluspec, for multiple retinal disorders; Sandoz to commercialise across the EU, expanding access to affordable biologics.
Alembic Pharmaceuticals Wins US FDA Approval for Generic Efinaconazole Topical Solution
Alembic Pharmaceuticals receives US FDA approval for generic efinaconazole topical solution, targeting a US market estimated at USD 500 million.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy